Difference between revisions of "Part:BBa K4165148"
Line 3: Line 3:
 
<partinfo>BBa_K4165148 short</partinfo>
 
<partinfo>BBa_K4165148 short</partinfo>
  
−
Tau binding peptide targeting the PHF seed of Tau
+
A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.
  
 
===Usage and Biology===
 
===Usage and Biology===
  
−
W-MINK is a peptide with amino acid sequence of DVWMINKKRK, it is designed to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. W-MINK can bind to PHF* in a mean that can disrupt the interface between each PHF* and consequently reduce the aggregates. Its IC<sub>50</sub> for inhibition of tau aggregates were 1.1 μM.
+
W-MINK is a peptide (DVWMINKKRK), acquired by mirror image phage display to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. W-MINK can bind to PHF* in a mean that can disrupt the interaction between fibrils and consequently reduce the aggregates.
 +
 
 +
 
 +
<p style=" font-weight: bold; font-size:12px;"> IC<sub>50</sub> = 1.1 μM. </p>
  
 
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
Line 22: Line 25:
  
 
<html>
 
<html>
−
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/wmink.png" style="margin-left:200px;" alt="" width="300" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/wmink.png" style="margin-left:300px;" alt="" width="300" /></p>
 
</html>
 
</html>
 
                             Figure 1.: Predicted 3D structure of Synthetic peptide W-MINK.
 
                             Figure 1.: Predicted 3D structure of Synthetic peptide W-MINK.
Line 31: Line 34:
  
 
<html>
 
<html>
−
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/wmink-qa.png" style="margin-left:75px;" alt="" width="800" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/wmink-qa.png" style="margin-left:50px;" alt="" width="800" /></p>
 
</html>
 
</html>
  

Revision as of 14:01, 11 October 2022


W-MINK Peptide

A synthetic peptide that is used for targeting misfolded tau protein (BBa_K4165009) as it binds to PHF6 of tau fibrils.

Usage and Biology

W-MINK is a peptide (DVWMINKKRK), acquired by mirror image phage display to inhibit the fibrilization of tau which is one of the main drivers of Alzheimer’s disease and other dementia diseases. PHF* (VQIINK) is the site that derive tau aggregation. W-MINK can bind to PHF* in a mean that can disrupt the interaction between fibrils and consequently reduce the aggregates.


IC50 = 1.1 μM.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

W-MINK is modeled by AlphaFold2, Apptest, ITASSER and RosettaFold, best model obtained from AlphaFold2 



                            Figure 1.: Predicted 3D structure of Synthetic peptide W-MINK.


Table 1: Quality assessment parameters of W-MINK model.

References

1. Seidler, P. M., Boyer, D. R., Rodriguez, J. A., Sawaya, M. R., Cascio, D., Murray, K., ... & Eisenberg, D. S. (2018). Structure-based inhibitors of tau aggregation. Nature chemistry, 10(2), 170-176.